Abivax SA Sponsored ADR
ABVX Healthcare Biotechnology
- EPS
- −98.8%
- Free cash flow
- −48.3%
- Total debt
- −98.5%
Quarter to June 2026, against a year earlier
Follow ABVX
Alert me
Abivax SA Sponsored ADR (ABVX) Operating cash flow
Abivax SA Sponsored ADR's operating cash flow for fiscal 2025 was −$182.3M, compared with −$166.7M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$225.9M. Over the past ten years it has ranged from −$182.3M (fiscal 2025) to −$17.2M (fiscal 2018) — the current reading is the lowest in ten years. Operating cash flow has fallen for 7 consecutive fiscal years. Abivax SA Sponsored ADR ranks 554th of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | −$182.3M | — |
| FY2024 | −$166.7M | — |
| FY2023 | −$105.1M | — |
| FY2022 | −$56.8M | — |
| FY2021 | −$54.0M | — |
| FY2020 | −$34.0M | — |
| FY2019 | −$30.7M | — |
| FY2018 | −$17.2M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Jun 2026 | −$60.1M | — |
| Mar 2026 | −$59.1M | — |
| Dec 2025 | −$21.1M | — |
| Sep 2025 | −$85.6M | — |
| 10 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| CORT Corcept Therapeutics Incorporated compare | $198.1M |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | −$59.1M |
| AXSM Axsome Therapeutics, Inc. compare | −$81.8M |
| RYTM Rhythm Pharmaceuticals, Inc. compare | −$81.8M |
| ORKA Oruka Therapeutics, Inc. compare | −$100.9M |
| ABVX Abivax SA Sponsored ADR | −$225.9M |
| SYRE Spyre Therapeutics, Inc. compare | −$249.3M |
| PRAX Praxis Precision Medicines, Inc. compare | −$305.1M |
| CYTK Cytokinetics, Incorporated compare | −$572.0M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item